ArticleBreast (Edinburgh, Scotland)2022

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.

Adrià Bernat-Peguera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.